Navigation Links
ev3 Inc. Accepts Resignation of Dr. John Simpson
Date:2/8/2008

PLYMOUTH, Minn., Feb. 8 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, today announced the resignation of Dr. John Simpson from his position as Chief Scientist and from the company's board of directors effective February 7, 2008.

"Over the last thirty years, few people have shaped the treatment of cardiovascular disease as much as Dr. John Simpson with his numerous inventions and vision for improving the lives of patients worldwide," said Jim Corbett, chairman, president and chief executive officer of ev3 Inc. "He leaves a legacy of innovation and a foundation on which we intend to build in our effort to improve patient treatment."

With the resignation of Dr. Simpson, the ev3 board of directors has nine members, of which six are independent directors.

About ev3 Inc.

Since its founding in 2000, ev3 has been dedicated to improving the lives of patients with vascular disease through the development of innovative endovascular therapies. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today - peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolic coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at http://www.ev3.net.

ev3, the ev3 logo and FoxHollow are trademarks of ev3 Inc., registered in the U.S. and other countries. All trademarks and trade names referred to in this press release are the property of their respective owners.


'/>"/>
SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
2. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
3. American Stock Exchange Accepts Encisions Plan to Regain Compliance
4. Governor Rendell Accepts National Health Care Reform Pioneer Award
5. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
6. Lieutenant Governor Catherine Baker Knoll Accepts Women in Government Presidential Leadership Award
7. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
8. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
9. Aflac Announces Resignation of U.S. Marketing Officer
10. Genta Announces Resignation of Dr. Betsy McCaughey from Board of Directors
11. Protalix BioTherapeutics Announces Resignation of Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... RawTrition now brings you BioEnergy which is a powder ... , RawTrition is taking nutrients to the next level! The superfoods ... its raw form (unlike the synthetically made options that are on the market). , ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading ... patient care management module. Using this new feature, sleep physicians can now predict ... on continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
Breaking Medicine Technology: